Aligos Therapeutics (ALGS) Earnings Date, Estimates & Call Transcripts $5.71 +0.11 (+1.96%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$5.72 +0.00 (+0.09%) As of 07:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Aligos Therapeutics Earnings Summary Aligos Therapeutics issued Q1 2026 earnings on May 7, 2026, reporting an EPS of -$2.21, which beat analysts' consensus estimates of -$2.29 by $0.08. Quarterly revenue was reported to be $2.83 million, above analyst estimates of $0.25 million. With a trailing EPS of -$8.69, Aligos Therapeutics' earnings are expected to grow next year, from ($7.54) to ($4.32) per share. Upcoming Q2 Earnings DateAug. 5Before Market OpensEstimatedConsensus EPS (May. 7) -$2.29 Actual EPS (May. 7) -$2.21 Beat By $0.08 Actual Revenue (May. 7) $2.83MQ1 2026 Earnings ResourcesQ1 2026 Earnings Report Press Release (8-K) Quarterly Report (10-Q)ALGS Upcoming EarningsAligos Therapeutics' next earnings date is estimated for Wednesday, August 5, 2026, based on past reporting schedules. Powered by Get Aligos Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aligos Therapeutics and other key companies, straight to your inbox. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Estimated and Actual Earnings DataALGS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ALGS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Aligos Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20261-$2.53-$2.53-$2.53Q2 20261-$0.75-$0.75-$0.75Q3 20261-$3.16-$3.16-$3.16Q4 20261-$2.22-$2.22-$2.22 FY 2026 4 -$8.66 -$8.66 -$8.66 Q1 20271-$1.03-$1.03-$1.03Q2 20271-$1.04-$1.04-$1.04Q3 20271-$1.06-$1.06-$1.06Q4 20271-$0.44-$0.44-$0.44 Aligos Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/5/2026(Estimated)--------5/7/2026Q1 2026-$2.29-$2.21+$0.08-$2.21$0.25M$2.83M3/5/2026Q4 2025-$2.09-$1.91+$0.18-$1.91$0.27M$0.17M11/6/2025Q3 2025-$2.09-$3.04 -$0.95-$3.04$0.50M$0.74M8/6/2025Q2 2025-$2.35-$1.53+$0.82-$1.53$0.43M$0.97M5/6/2025Q1 2025-$2.80-$2.11+$0.69-$2.11$0.33M$0.31M3/10/2025Q4 2024-$2.63-$13.08 -$10.45-$13.08$0.43M$0.63M11/6/2024Q3 2024-$2.15-$3.07 -$0.92-$3.07$1.00M$1.27M8/6/2024Q2 2024-$4.00$0.75+$4.75$0.03-$1.06M Data powered by Fiscal.ai. Aligos Therapeutics Earnings - Frequently Asked Questions When is Aligos Therapeutics' earnings date? Aligos Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 5th, 2026 based off last year's report dates. Learn more on ALGS's earnings history. Did Aligos Therapeutics beat their earnings estimates last quarter? In the previous quarter, Aligos Therapeutics (NASDAQ:ALGS) reported ($2.21) earnings per share (EPS) to beat the analysts' consensus estimate of ($2.29) by $0.08. Learn more on analysts' earnings estimate vs. ALGS's actual earnings. How much revenue does Aligos Therapeutics generate each year? Aligos Therapeutics (NASDAQ:ALGS) has a recorded annual revenue of $2.19 million. How much profit does Aligos Therapeutics generate each year? Aligos Therapeutics (NASDAQ:ALGS) has a recorded net income of -$24.19 million. ALGS has generated -$8.69 earnings per share over the last four quarters. What is Aligos Therapeutics' EPS forecast for next year? Aligos Therapeutics' earnings are expected to grow from ($7.54) per share to ($4.32) per share in the next year. More Earnings Resources from MarketBeat Related Companies Alpha Cognition Earnings Results Genelux Earnings Results Tharimmune Earnings Results Cardiff Oncology Earnings Results Pyxis Oncology Earnings Results Cypherpunk Technologies Earnings Results Kalaris Therapeutics Earnings Results Equillium Earnings Results Rani Therapeutics Earnings Results ALT5 Sigma Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingMeta Platforms 10% Layoff Raises a Bigger Question About AI SpendingTarget Shows Strengths, But Analysts Want to See MoreFreight Boom: The Hormuz Blockade PaydayTJX Companies Fires on All Cylinders With 9% Revenue GrowthAnalog Devices Provides Much-Needed Pullback: How Low Can It Go?USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms This page (NASDAQ:ALGS) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...The Oxford Club | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
